Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - Thrombosis research, 2021 - Elsevier
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
被引用次数：21 相关文章

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - inria.hal.science
BACKGROUND: Direct oral anticoagulants (DOAC) use remains challenging in obese
patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.

A Ballerie, N Van R, K Lacut, H Galinat… - Thrombosis …, 2021 - europepmc.org
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - univ-angers.hal.science
BACKGROUND: Direct oral anticoagulants (DOAC) use remains challenging in obese
patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - hal.univ-brest.fr
BACKGROUND: Direct oral anticoagulants (DOAC) use remains challenging in obese
patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - hal.science
BACKGROUND: Direct oral anticoagulants (DOAC) use remains challenging in obese
patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - univ-rennes2.hal.science
BACKGROUND: Direct oral anticoagulants (DOAC) use remains challenging in obese
patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat… - Thrombosis …, 2021 - thrombosisresearch.com
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
[PDF] hal.science

[PDF][PDF] Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - hal.science
Objective To assess rivaroxaban and apixaban concentrations at different time-points after
intake, in obese patients followed at a thrombosis center and treated for VTE; to define …